Ignite Creation Date:
2024-05-06 @ 1:04 AM
Last Modification Date:
2024-10-26 @ 10:58 AM
Study NCT ID:
NCT01722227
Status:
WITHDRAWN
Last Update Posted:
2017-02-09
First Post:
2012-11-02
Brief Title:
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
Sponsor:
University at Buffalo
Organization:
University at Buffalo
Study Overview
Official Title:
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
Status:
WITHDRAWN
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No Funding Received from ADA
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is the first prospective randomized double-blind placebo-controlled study to investigate the effect of a GLP-1 analog specifically liraglutide on blood glucose levels and variability in subjects with type 1 diabetes treated with insulin Liraglutide is the preferred GLP-1 analog for this study because the pharmacokinetics and pharmacodynamics of the drug are consistent with a sustained duration of action The current gold standard for management of type 1 diabetes is based on insulin replacement with novel analogs with specified pharmacodynamic profiles or with unique insulin delivery systems insulin pump therapy No other adjuvant therapy has demonstrated sustained benefit in this population This study will also investigate the effect of liraglutide on suppression of glucagon secretion during meal challenges This is of particular importance since in the absence of insulin secretion from the β-cell there is no paracrine inhibition of glucagon secretion by the α-cell Dysregulation of glucagon secretion may impact the glycemic control and overall pathogenesis in those with type 1 diabetes The use of CGM technology in this study will allow us to determine the rapidity consistency and sustainability of any response to liraglutide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1-12-CT-20 | OTHER_GRANT | American Diabetes Association | None |